The incidence of fungal infections has increased significantly over the past decades. Very often these infections are associated with biofilm formation on implanted biomaterials and/or host surfaces. This has important clinical implications, as fungal biofilms display properties that are dramatically different from planktonic (free-living) populations, including increased resistance to antifungal agents. Here we describe a rapid and highly reproducible 96-well microtiter-based method for the formation of fungal biofilms, which is easily adaptable for antifungal susceptibility testing. This model is based on the ability of metabolically active sessile cells to reduce a tetrazolium salt (2,3-bis(2-methoxy-4-nitro-5-sulfo-phenyl)-2H-tetrazolium-5-carboxanilide) to water-soluble orange formazan compounds, the intensity of which can then be determined using a microtiter-plate reader. The entire procedure takes approximately 2 d to complete. This technique simplifies biofilm formation and quantification, making it more reliable and comparable among different laboratories, a necessary step toward the standardization of antifungal susceptibility testing of biofilms.
INTRODUCTION
Fungal infections caused by yeasts and moulds represent an escalating problem in health care, as advances in modern medicine prolong the lives of not only severely ill patients, including HIVinfected, cancer, transplant, surgical and ICU patients, but also newborn infants. Use of broad-spectrum antibiotics, neutropenia, parenteral nutrition, indwelling catheters, immunosuppression and disruption of mucosal barriers due to surgery, chemotherapy and radiotherapy represent the most important predisposing factors for these infections. Candida spp., Aspergillus spp. and Cryptococcus neoformans are among the most common etiologic agents of fungal infections 1, 2 . Fungi, being eukaryotic cells and more complex than bacteria, cause infections that are often difficult to diagnose and treat, and carry unacceptably high mortality rates 3 .
Most microbiology investigations have traditionally used freeliving (planktonic) cells in pure culture, resulting in the common perception that microorganisms are independent unicellular life forms. However, in their natural ecosystems, most microbes exist as attached communities of cells within an organized biofilm and rarely as planktonic organisms 4 . Thus, a biofilm is defined as a surface-associated and highly structured community of microorganisms that are enclosed within a protective extracellular matrix. Microbial biofilms can form in nature but also inside a host, and in recent years, there has been an increased appreciation of the role that microbial biofilms play in human medicine: it is now estimated that about 65% of all human infections have a biofilm etiology 5 .
Many different groups of investigators have demonstrated that fungal biofilms show increased levels of resistance against various classes of antifungal drugs, most notably azoles and polyenes 6 . This resistance is likely multifactorial and, among other mechanisms, may be due to (i) high cellular density within the biofilm; (ii) the protective effect of the biofilm exopolymeric material; (iii) differential expression of genes linked to resistance, including those encoding efflux pumps; and (iv) the presence of a subpopulation of 'persister' cells. However, newer antifungal agents, such as the echinocandins and liposomal formulations of amphotericin B, display increased efficacy against fungal biofilms 7, 8 . Of note, the commonly used Clinical and Laboratory Standards Institute (CLSI) broth microdilution techniques for antifungal susceptibility testing are based on the use of planktonic populations and will not enable prediction of the drugs' efficacy against fungal biofilms 9 . The increased levels of resistance typically associated with biofilms underscore the importance of developing standardized assays to test biofilm antifungal susceptibilities and to thereby systematically determine the effectiveness of different antifungal agents and regimens against fungal biofilms.
Traditionally, most models for the formation of microbial biofilms, including those formed by fungal species, are cumbersome, requiring expert handling, longer processing times and the use of specialized equipment not generally available in a regular microbiology laboratory. In the case of fungal biofilms, models used by different groups of investigators include the use of catheter disks, sheets and tubing from a variety of materials normally placed inside some type of sterile receptacle, glass and plastic slides, a perfused biofilm fermentor, microfermentors, cylindrical cellulose filters, acrylic strips and discs, germanium substratum, tissue culture flasks, syringes, modified Robbins devices, the Calgary biofilm device, the CDC reactor and so on, also including both biofilms formed under static and flow-through conditions [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . Perhaps with the exception of the Calgary biofilm device, most of these models are complex, technically demanding and generally not amenable to high-throughput screening, as relatively few equivalent biofilms can be produced at the same time 6 .
Here we describe a rapid and robust 96-well microtiter plate model for the formation of fungal biofilms. This technique involves p u o r G g n i h s i l b u P e r u t a Nformation of multiple equivalent fungal biofilms on the bottom of wells of microtiter plates, coupled with a colorimetric method that measures the metabolic activities of cells within the biofilm based on the reduction of 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT). Upon processing by metabolically active cells, the XTT yields a water-soluble formazan-colored product that can be measured spectrophotometrically in a microtiter plate reader (Fig. 1) . We (and others) have previously shown that the XTT-reduction assay shows excellent correlation between cellular density and metabolic activity, thus providing a semiquantitative measurement of biofilm formation [22] [23] [24] [25] [26] . This colorimetric assay is noninvasive and nondestructive, requiring minimal post-processing of samples as compared with other alternative methods (such as viable cell counts) and has the additional advantage that, in contrast to other methods such as crystal violet staining and dry mass measurements 25, 27 , it correlates with cell viability, which is particularly useful for measuring the effects of drugs on biofilm cells. However, some caveats and limitations about the use of this reagent have been noted 27 . For example, results using the XTT-colorimetric assay to compare biofilm-forming ability by different isolates need to be interpreted with caution, as it has been reported that different fungal species and even strains from the same species show marked differences in their ability to metabolize the XTT substrate 27 . In addition, alterations in the metabolic states during the different phases of biofilm formation may lead to fluctuations in the ability of cells within the biofilms to metabolize this dye 23, 27 . Some more recent articles indicate that the use of other vital stains (SYTO9, propidium iodide), fluorogenic assays or bioluminescence may represent alternatives and have some practical advantages over the use of XTT 23, 24, 28 .
This 96-well microtiter plate model for biofilm formation was originally developed for Candida albicans and other Candida spp. 25 but more recently has successfully been adapted for the formation of biofilms by other biofilm-forming fungal species of clinical interest, such as Cryptococcus neoformans and Aspergillus fumigatus 29, 30 . Overall, this microtiter plate-based model of biofilm formation offers a simple, flexible, relatively inexpensive, accurate and reproducible alternative for biofilm formation that is compatible with the widely available 96-well microplate platform. It can be used to examine multiple parameters and factors influencing biofilm formation, to estimate the biofilm-forming ability of multiple fungal isolates and mutant strains and, more importantly for the purpose of these studies, it can be easily adapted for antifungal susceptibility testing of fungal biofilms following the procedures described below 25, 31, 32 .
Experimental design Fungal isolates. Candida albicans SC5314, A. fumigatus AF293 (NCPF 7367, CBS 101355) and C. neoformans H99 (serotype A) are all type strains that were used initially to optimize parameters of biofilm formation. Importantly, these are also the strains that were used for the corresponding genome sequencing projects of each fungal species and also represent parental strains used for the construction of a variety of mutants. These methods have been used to assess the biofilm-forming ability and antifungal susceptibility profiles of different clinical isolates of the three species and mutant strains, as well as representative isolates of other Candida spp. Stock cultures of these strains are typically prepared on Sabouraud dextrose agar plates or slopes and stored at 4 1C. For long-term storage, glycerol stocks and À70 1C are recommended.
Optimization of conditions. These procedures have already been optimized for each of the fungal species described here. Hence, we recommend readers to follow our suggested protocol, at least initially. On the basis of results obtained from their first experiments, readers can then try to optimize certain parameters as they apply to their own experimental design or particularities of their model (i.e., testing of clinical isolates, testing of different fungal species, testing biofilm-forming ability by mutant strains and testing different antifungal agents).
MATERIALS

REAGENTS
. Sabouraud Steps 6-7
Steps 8-11
Steps 12-17
Steps 18-23 ! CAUTION Most fungal organisms to be tested here have the potential to cause infections in humans, particularly immunosuppressed individuals. Thus, adequate biosafety practices need to be followed. For C. neoformans and Aspergillus spp., all manipulations should be performed within a biological safety cabinet (in the case of Aspergillus spp., this is important also to prevent contamination of other laboratory surfaces). Work with Candida spp. can be performed on an open bench, but proper microbiological handling techniques to prevent contamination and universal precautions must be followed.
2|
Harvest cells from the overnight-grown liquid cultures (for Candida spp. and C. neoformans) or from the conidial suspension (for A. fumigatus) by centrifugation (approximately 3,000g for 5 min at 4 1C), remove supernatant and wash twice in sterile PBS (by resuspending the pellet in approximately 20 ml of ice-cold buffer, vortexing vigorously, followed by centrifugation as mentioned above). m CRITICAL STEP Because fungal cells tend to settle and/or aggregate, the cell suspensions must be vortexed vigorously after washings and before pipetting for the different manipulations used in this and successive steps.
3|
Resuspend the final pellet of cells in approximately 20 ml of the appropriate medium that has been prewarmed to 37 1C: RPMI 1640 for Candida and Aspergillus and DMEM for Cryptococcus.
4| From the resulting cell suspension, prepare 1:100 and/or 1:1,000-fold dilutions in the same medium and count using a hemocytometer and a bright field microscope with a Â40 objective.
5| After counting, calculate the volumes needed to prepare a suspension of cells at a final density of 1.0 Â 10 6 cells ml À1 in RPMI 1640 for Candida, 1.0 Â 10 5 cells ml À1 in RPMI 1640 for Aspergillus or 1.0 Â 10 7 cells ml À1 in DMEM for Cryptococcus. The total volume needed will depend on the aggregate number of wells (or plates) that need to be seeded for biofilm formation for each isolate under investigation. m CRITICAL STEP The fungal cell density of the initial inoculum is very important for correct biofilm development, as quorum-sensing mechanisms play an important role in biofilm formation. result in poor biofilms. The cell densities for the inocula suggested here have been empirically optimized for experiments using 96-well microtiter plates for each different fungal species.
Biofilm formation TIMING B24 h 6| Open as many 96-well microtiter plates as needed according to the experimental design (these plates are sterile and come individually packaged). We recommend performing a minimum of 2-4 replicates (entire rows of the microtiter plate(s)) for each combination of fungal isolate/antifungal agent to be tested.
7| From the standardized inoculum prepared in Step 5, pipette 100 ml (for Candida) or 200 ml (for Aspergillus and C. neoformans) into selected wells of the microtiter plate(s). Typically, wells in column 12 on each plate should remain unseeded, as these eight wells will act as negative background controls during subsequent analyses. Repeat as necessary for each different fungal isolate to be tested. m CRITICAL STEP It is important that the seeding of the wells occurs promptly after preparation of the inocula. m CRITICAL STEP If multiple rows are present in the same plate or the entire plate or if multiple plates are to be seeded with the same fungal isolate, the use of a multichannel pipette is strongly recommended for this and the successive steps.
8| When all the selected wells have been seeded, cover the entire microtiter plate with its original lid, seal with parafilm, place inside an incubator and incubate statically for 24 h at 37 1C. For Candida spp., Aspergillus spp. and C. neoformans, after 24-to 48-h incubation, biofilms should already display the complex three-dimensional architecture characteristic of multicellular communities, and the resulting biofilms can be used for antifungal susceptibility testing. However, after seeding the plates, the time of incubation for biofilm formation may be varied depending on the specific objectives of the study: for example, if the main objective of the study is examination of initial adherence, the incubation time can be reduced to 4 h; other investigators may want to study 'fully mature' biofilms after 72-96 h incubation. ! CAUTION Note that A. fumigatus biofilms with greater than 48 h growth may begin to sporulate, which could create post-processing problems and increase the possibilities for unwanted laboratory contamination.
9| After biofilm formation, aspirate the medium carefully as not to touch and disrupt the biofilm. The best way to do this is, using a multi-channel pipette, to angle the pipette tips toward the corners of the wells, thereby minimizing contact with the biofilm.
10| Using a multichannel pipette, wash plates three times in sterile PBS (200-300 ml per well) to remove planktonic and/or nonadherent cells that remain in the wells.
11|
After each wash, the microtiter plates should be drained in an inverted position by blotting with paper towels to remove any residual PBS. Biofilms are now ready to be processed for antifungal susceptibility testing assays. m CRITICAL STEP The washing procedures are critical, with the main emphasis on preserving biofilm integrity. Other methodologies can potentially be used, such as gently flicking the plates to discard the liquid contents, squirting buffer from a bottle, using an automated microtiter plate washer and so on. Typically, the fungal biofilms are strongly attached to the bottom of the wells of microtiter plates, and these washing procedures should not disrupt the preformed biofilms. In any case, at the end of the washing procedures, any well with clearly disrupted biofilm layer at the bottom (normally, this is visible by the naked eye) should be excluded from further subsequent calculations. This is one of the main reasons why we recommend performing sufficient replicates for each isolate/antifungal drug combination to be tested. m CRITICAL STEP The ability to form multiple equivalent biofilms in a reproducible manner is a requirement for the success of these techniques. Thus, we recommend that when these protocols are followed for the very first time, and before proceeding to antifungal susceptibility testing, investigators corroborate that they have indeed been able to form multiple equivalent biofilms in the wells of the microtiter plate(s). At this point, after biofilm formation, the XTT/menadione reagent can be added and the resulting color read using a microtiter plate reader (see below, follow Steps 18-22; see also ANTICIPATED RESULTS). The same is true if assessment of biofilm-forming ability of fungal isolates (and not antifungal susceptibility testing) is the main objective of a particular set of experiments.
? TROUBLESHOOTING Preparation of antifungal agents and antifungal challenge of preformed biofilms TIMING B24 h 12| From the stock solution of each antifungal agent, a final 'high' working concentration is prepared in RPMI 1640 medium. Typical high concentrations are 1,024 mg ml À1 for fluconazole and 16 mg ml À1 for both amphotericin B and caspofungin. Other concentrations may be used for different agents. m CRITICAL STEP If testing experimental and/or new agents with unknown activity against biofilms, we recommend to start with high concentrations of the drug, normally up to 100-1,000 times higher than one would use against planktonic populations. 13| Using a multichannel pipette, add 200 ml of the high working concentration of antifungal agent to the corresponding wells on column 1 of each microtiter plate containing fungal biofilms, being careful not to touch or otherwise disrupt the biofilms.
14| Add 100 ml of RPMI 1640 to each well in columns 2-10. Add 100 ml of RPMI 1640 to wells in column 11; these will act as the positive control (biofilm not exposed to antifungal agent). Wells in column 12 remain empty as negative controls.
15| Remove 100 ml of antifungal agent from the wells of column 1 and add to the adjacent wells in column 2 (already containing 100 ml of medium). The contents are then mixed by gently pipetting up and down to perform a serial doubling dilution, and the pipette tips are removed.
16| Remove 100 ml of antifungal agent from the wells of column 2 and add to the adjacent wells in column 3 (already containing 100 ml of medium). Mix gently and repeat moving right until the wells of column 10, after which the final 100 ml volume from the wells of column 10 after mixing is discarded. You have just created serial doubling dilutions of your agent(s) of interest, from column 1 (most concentrated) to column 10 (least concentrated), with unchallenged biofilms in column 11 serving as positive controls.
17| Cover the plates with their lids, seal with parafilm and incubate for 24 h at 37 1C. Other incubation times can be used depending on the experimental design or particularities of the antifungal agent(s) being tested.
Postprocessing and measurement of metabolic activity after antifungal treatment TIMING B2-3 h 18| Thaw as many tubes containing 10 ml of the XTT solution as required for the experimental design (one per plate). To each tube, add 1 ml of the stock solution of menadione to achieve a final menadione concentration of 1 mM. For uniformity, if multiple plates are processed at the same time, we recommend pooling all the resulting XTT/menadione tubes into a single solution in a clean sterile container.
19| Using a multichannel pipette, add 100 ml of the XTT/menadione solution to each well containing a prewashed biofilm as well as to negative control wells (for the measurement of background XTT-colorimetric levels).
20| Cover the plates in aluminum foil and incubate in the dark for 2-3 h at 37 1C. ? TROUBLESHOOTING Troubleshooting advice can be found in Table 1 . 
ANTICIPATED RESULTS
As emphasized before, it is important that multiple equivalent biofilms are formed in individual wells of the microtiter plates. Figure 2 shows XTT-colorimetric readings (OD 490 values) for each of ten biofilms of C. albicans strain SC5314 formed in each of the eight different rows of the same 96-well microtiter plate (a total of 80 replicates). Results for the different rows were compared by one-way analysis of variance and using the Bartlett's test for homogeneity of variances and the Bonferroni's multiple comparison post-test. No statistically significant differences were noted when comparing all pairs of rows to each other (P40.05). Table 2 shows typical results, expressed as SMIC50s and SMIC80s, of antifungal susceptibility testing for multiple C. albicans isolates against three of the most common antifungal agents used clinically. Note that typically biofilms are intrinsically resistant to fluconazole and most other azole derivatives. Amphotericin B is active against biofilms but normally at concentrations considered to be high, due to the intrinsic toxicity associated with this polyene antibiotic. Caspofungin, a representative of the echinocandin class of new antifungal agents, shows excellent in vitro activity against biofilms formed by most C. albicans isolates. Figure 3 shows the activity of caspofungin at different concentrations against C. albicans biofilms, expressed as percentage of colorimetric readings for XTT-reduction assays as compared with control wells. Figure 3 | Activity of different caspofungin concentrations against preformed biofilms of C. albicans SC5314. Values are expressed as average percentage of colorimetric readings for XTT-reduction assays as compared with control wells. Note that, as previously described, caspofungin loses efficacy at nonphysiological high concentrations. This has been referred to as the 'paradoxical' or 'Eagle' effect.
